Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 4Urothelial Cancer 2Urinary Bladder Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non Small Cell Lung Cancer NSCLC 1Nasopharyngeal Carcinoma 1Metastatic Urothelial Cancer 1Metastatic Adenocarcinoma of the Pancreas 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 2Paclitaxel 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sacituzumab govitecan 1pegfilgrastim 1atezolizumab 1Gemcitabine 1Filgrastim 1Epirubicin 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Triple Negative Breast Neoplasms × Gemcitabine × Clear all
NCT02819518 2024-11-27

KEYNOTE-355

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 41 charts 1 FDA
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡